Compare BioNano Genomics Inc (BNGO) vs NICE Ltd (NICE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs NICE Ltd — how do they compare? BioNano Genomics Inc trades at $1.2 (market cap $13.31M), while NICE Ltd trades at $101 (market cap $5.99B). The key difference: NICE Ltd is far larger — about 450× BioNano Genomics Inc's market cap, and NICE Ltd is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | NICE | |
|---|---|---|
Market Cap | $13.31M | $5.99B |
Sector | Health | Technology |
52-Week High | $4.92 | $153.44 |
52-Week Low | $1.06 | $83.15 |
Enterprise Value | $15.92M | $5.72B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.16, up 5.45% today, with a bullish technical signal from moving averages. The company shows improving financial trends with revenue stabilizing around $29M annually and narrowing losses from -$232M in 2023 to -$26M in 2025. Recent earnings beats and positive news flow around optical genome mapping adoption support momentum.
While BNGO demonstrates operational improvement and analyst support (57% buy ratings), the stock faces significant risks including persistent negative profitability, cash burn requiring ongoing financing, and competitive pressures in genomic technology. The current valuation appears attractive on P/S and P/B metrics but reflects the company's pre-profitability stage.
NICE stock trades at $101.85, up 4.88% today, showing strong momentum after exceeding Q2 2026 earnings expectations with $2.70 EPS versus $2.63 expected. The company maintains solid fundamentals with 65.12% gross margins and 13.86% net income margin, while technical indicators show bullish momentum with key resistance at $103. Recent partnerships with RingCentral and ESG initiatives highlight strategic growth positioning.
The outlook remains positive with analyst consensus target of $115 suggesting 13% upside potential. Key risks include competitive pressures in customer engagement software and potential margin compression as revenue growth outpaces profit growth. Institutional ownership trends show mixed activity with some firms increasing positions while others trim holdings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About NICE Ltd
NICE Ltd. is a global leader in both enterprise software and cloud computing, specializing in customer experience and financial crime prevention solutions. The company's platform utilizes advanced analytics, AI, and automation to help organizations enhance customer interactions, ensure compliance, and combat fraud. NICE serves a diverse client base, including contact centers, financial institutions, and government agencies, by optimizing operations and improving service quality.
Read more on NICE →
